Search Bar & Filters
Found 42 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are conducting a Phase 1 clinical trial to evaluate the safety and immune response of the rVSV94G-SUDV-GP vaccine designed to prevent Sudan Virus Disease in healthy adults aged 18 to 50 years. This study uses a randomized, observer-blind, placebo-controlled, dose-escalation design to carefully assess different dose levels of the vaccine. The trial is led by the International AIDS Vaccine Initiative and involves close monitoring for safety and vaccine response.
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects vision. This study aims to learn if a medicine called tiespectus also known as MK-8748 or EYE201 can treat NVAMD as well as the standard treatment called aflibercept. The trial is a pivotal Phase 23 study that compares these treatments in people newly diagnosed with NVAMD. Participants are randomly assigned to one of three groups one group receives a low dose of tiespectus, another receives a high dose of tiespectus, and the third group receives aflibercept. Those in the tiespectus groups get three initial injections every 4 weeks, then continue injections every 8 weeks until week 48, followed by treatments at intervals based on their individual response up to week 92. The aflibercept group receives three initial injections followed by injections every 8 weeks until week 92. During the study, participants are regularly assessed for changes in their best-corrected visual acuity using ETDRS letters from baseline to one year. Other evaluations include eye imaging to measure retinal thickness and monitoring for any adverse events up to approximately 96 weeks. The study lasts over one year with ongoing visits to track treatment response and safety.
Actively Recruiting
Researchers are investigating new treatments for diabetic macular edema DME, a condition that can cause vision loss. This trial aims to compare the effects of a new medicine called MK-8748 with the current standard treatment, aflibercept, to see if MK-8748 works as well. The study focuses on adults with type 1 or type 2 diabetes who have vision decrease due to DME. Participants will be randomly assigned to one of three groups two groups receive different doses of MK-8748 via injections into the eye, starting with five doses every 4 weeks, then every 8 weeks until week 48, followed by treatment intervals based on individual response up to week 100. The third group receives aflibercept injections on a similar schedule for up to 100 weeks. The study is double-masked and multicenter, designed to carefully compare these treatments. During the trial, participants will have regular eye examinations, including measurements of visual acuity and retinal thickness, along with imaging tests such as optical coherence tomography and fluorescein angiography. Researchers will monitor changes in vision and eye condition over one to two years, assess treatment safety, and track adverse events and drug levels. The main outcome measured is the change in best-corrected visual acuity after one year of treatment.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and how the new drug NNC0721-8060 works in adults living with overweight or obesity. This phase 1 study includes participants aged 18 to 55 years with a body mass index BMI between 27.0 and 34.9 kgm. The study compares NNC0721-8060 to semaglutide and a placebo, all given by subcutaneous injection. Participants will be randomly assigned to receive subcutaneous injections of NNC0721-8060, semaglutide, or placebo. The study includes multiple parts lasting from 36 to 113 days, during which the effects and safety of the treatments will be monitored closely. During the study, participants will undergo medical exams, vital sign checks, electrocardiograms, and laboratory tests. Researchers will track treatment-emergent adverse events and changes in body weight over time. The study also measures how the drug moves through and affects the body. Participants health and safety will be monitored throughout, with the total study duration depending on the treatment part they are assigned to.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.
Actively Recruiting
Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a randomized, double-blind, placebo-controlled Phase I study to evaluate the safety, tolerability, and pharmacokinetics of a single dose of IBI3032 in healthy adults. This study is a single ascending dose trial involving approximately 32 healthy participants and is intended for research purposes only, not treatment of any condition. Participants will be divided into four groups cohorts of eight people each. In each cohort, six participants will receive a single oral dose of IBI3032, and two will receive a placebo, all given while fasting. The different cohorts will receive escalating doses of IBI3032 or placebo. The study includes a screening period of four weeks, followed by dosing and then a safety follow-up lasting 15 days. During the study, participants will undergo safety and laboratory assessments to ensure they are healthy and monitor any adverse effects from the drug or placebo. Researchers will track serious and non-serious adverse events up to 15 days after dosing. Blood samples will be collected up to 168 hours post-dose to study how the drug is processed in the body. Overall participation will last through the screening, dosing, and 15-day safety follow-up periods.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, side effects, and immune response triggered by various doses and formulations of investigational vaccines targeting Respiratory Syncytial Virus RSV and human Metapneumovirus hMPV in both younger and older healthy adults. This study involves different age groups including younger adults aged 18 to 49 years and older adults aged 60 to 80 years. The trial is conducted in phases to carefully monitor how these vaccines perform and their safety profiles. Participants receive a single dose of one of several investigational vaccines or a control vaccine or placebo, administered intramuscularly on Day 1. Younger adults receive one of several RSVhMPV or hMPV vaccine formulations at varying doses during Phase 1, while older adults receive similar vaccines in both Phase 1 and Phase 2. The study compares low, medium, and high doses across different vaccine types to understand immune responses and safety. During the study, participants are monitored for side effects and immune reactions from Day 1 through up to 24 months depending on the group. Assessments include tracking injection site reactions, systemic symptoms, adverse events, and laboratory tests before and after vaccination. Immune responses are measured by evaluating virus neutralization titers at several time points. Safety is closely observed with follow-up visits and reporting of any serious or medically attended events over the study duration.
Actively Recruiting
Healthy Volunteer
This research aims to study LY4088044 in healthy adult participants to understand how well it is tolerated and to identify any side effects. The study is a Phase 1, randomized, double-blind, placebo-controlled trial designed to gather basic science data on safety, tolerability, pharmacokinetics, and pharmacodynamics of LY4088044. The study is sponsored by Eli Lilly and Company and focuses on healthy adults between 18 and 65 years old. Participants will receive LY4088044 or placebo administered either intravenously IV or subcutaneously SC in different dosing parts single-ascending dose SAD IV, SAD SC, and multiple-ascending doses MAD IV. The study is organized in parallel groups with randomized allocation, and the dosing routes and schedules vary by part. The intervention aims to assess how the drug enters and leaves the bloodstream and its effects on protein levels in skin samples. Participants will be involved for up to approximately 92 weeks, excluding screening. During this time, blood tests will monitor LY4088044 levels and elimination, while skin samples will be analyzed for pharmacodynamic effects. Safety assessments include monitoring for serious adverse events related to the drug and routine evaluations such as vital signs, cardiac monitoring, and laboratory tests. The study tracks maximum drug concentration and exposure over about 190 days to evaluate treatment effects and tolerability.
1-10 of 42
1